Cargando…

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (teriflunomide, dimethyl fumarat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jalkh, Georges, Abi Nahed, Rachelle, Macaron, Gabrielle, Rensel, Mary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823546/ https://www.ncbi.nlm.nih.gov/pubmed/33375365 http://dx.doi.org/10.3390/vaccines9010012

Ejemplares similares

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence
por: Sabsabi, Sajida, et al.
Publicado: (2022)

Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies
por: Rensel, Mary
Publicado: (2019)

Newer therapies for multiple sclerosis
por: Coles, Alasdair
Publicado: (2015)

Diagnosis and Management of Progressive Multiple Sclerosis
por: Macaron, Gabrielle, et al.
Publicado: (2019)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
por: Feng, Jenny, et al.
Publicado: (2019)

Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting
por: Baldassari, Laura E, et al.
Publicado: (2019)

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
por: Pardo, Gabriel, et al.
Publicado: (2017)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Patient and Provider Insights into the Impact of Multiple Sclerosis on Mental Health: A Narrative Review
por: Davis, Bryan E., et al.
Publicado: (2021)

Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review
por: Lakin, Lynsey, et al.
Publicado: (2021)

Impact of aging on treatment considerations for multiple sclerosis patients
por: Macaron, Gabrielle, et al.
Publicado: (2023)

Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero
por: Smith, Andrew L, et al.
Publicado: (2019)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
por: Bross, Madeline, et al.
Publicado: (2020)

Newer anabolic therapies in osteopororsis
por: Mittal, Monika, et al.
Publicado: (2012)

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
por: Wiendl, Heinz, et al.
Publicado: (2021)

The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
por: Shahtaheri, Rahil Sadat, et al.
Publicado: (2020)

Bulbar Symptoms as an Unusual Presentation of Multiple Sclerosis: A Case Report
por: Kai, Martine, et al.
Publicado: (2022)

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
por: Schweitzer, F., et al.
Publicado: (2020)

Health economics of disease-modifying therapy for multiple sclerosis in the United States
por: Hartung, Daniel M.
Publicado: (2021)

Newer Antibacterials in Therapy and Clinical Trials
por: Paknikar, Simi S, et al.
Publicado: (2012)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

The Safety and Tolerability of Newer Antiepileptic Drugs in Children and Adolescents
por: Kayani, Saima, et al.
Publicado: (2012)

Newer agents in antiplatelet therapy: a review
por: Yeung, Jennifer, et al.
Publicado: (2012)

An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis
por: Wu, Gregory F., et al.
Publicado: (2016)

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
por: Grand′Maison, Francois, et al.
Publicado: (2018)

Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
por: Washington, Francesca, et al.
Publicado: (2021)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis
por: Beard, Katherine, et al.
Publicado: (2021)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Notes on the Newer Remedies
Publicado: (1893)

Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis
por: Liu, Caiyun, et al.
Publicado: (2022)

Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease
por: Zonszein, Joel, et al.
Publicado: (2016)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bdp9nckfrqvnq4jjpgau1m9p1q